Sage Therapeutics to lay off 1-third of workforce
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of an overhaul of its business and pipeline that’s expected to extend its cash runway.
Sage Therapeutics to lay off one-third of workforce
After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its leadership team.
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and Alzheimer's treatments.
Sage Cuts One-Third of Workforce After Clinical Trial Setbacks
Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple setbacks to its pipeline.
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich Schlieker, and Amy Schacterle. Chris Benecchi will be looking to take up the reins as Chief Operating Officer, overseeing several departments, while Greg Shiferman and Vanessa Procter will assume expanded leadership roles.
Sage Therapeutics Cutting Workforce by 33% -- Update
Sage on Thursday said the reorganization will affect more than 165 employees, representing about 33% of the Cambridge, Mass., company's total workforce and more than half of its research-and-development staff.
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term growth.
Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees
Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...
FierceBiotech1d
Sage lays off half of R&D team, shakes up C-suite again
Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading ...
SAGE Therapeutics’ Strategic Reorganization and Cautious Hold Rating Amid Development Setbacks
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating on October 10. Ami Fadia’s rating is ...
The Pharma Letter2h
Sage slashes further jobs as need to deliver deepens
US biotech company Sage Therapeutics is to slash a third of its remaining jobs - just a year after cutting 40% of its prior workforce.
Sage Therapeutics to lay off more than 165 employees
Sage Therapeutics said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce.
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc ...
Hosted on MSN4d
Werewolf Therapeutics jumps on early-sage data from lead program
Shares of Werewolf Therapeutics (NASDAQ:HOWL) added ~34% after announcing two partial remissions in an early-stage clinical program for WTX-124, one of its lead cancer candidates targeted at solid ...
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...